#Agenda | Merck Sharp & Dohme managing director Dr. Beaver Tamesis says they are now working to bring down the prices of experimental antiviral drug molnupiravir, which is being used for the treatment of COVID-19. The pharmaceutical company is set to produce 10 million doses of the drug by the end of 2021. Get updates via Viber: https://bit.ly/36uQLSo Join us on Telegram: https://t.me/onenewsph | ONE News

#Agenda | Merck Sharp & Dohme managing director Dr. Beaver Tamesis says they are planning to study the possibility of preventing COVID-19 from spreading in a household by taking molnupiravir. If approved by the US FDA, it would be the first oral antiviral medication for COVID-19. Get updates via Viber: https://bit.ly/36uQLSo Join us on Telegram: https://t.me/onenewsph | ONE News